Sarepta Therapeutics (SRPT) News Today $106.28 -2.13 (-1.96%) Closing price 04:00 PM EasternExtended Trading$106.22 -0.06 (-0.06%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?February 20 at 4:21 PM | insidermonkey.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Moderate Buy" from AnalystsFebruary 20 at 2:21 AM | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-three research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assiFebruary 20 at 2:19 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low - Here's WhySarepta Therapeutics (NASDAQ:SRPT) Reaches New 12-Month Low - Should You Sell?February 19 at 9:32 PM | marketbeat.comSolid Biosciences Soars 32% on Trial Data: 189% Upside from Here? (SRPT)Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?February 19 at 8:48 AM | marketbeat.comPeregrine Capital Management LLC Has $6.54 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Peregrine Capital Management LLC increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 28.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,804 shares of the biotechnology compaFebruary 19 at 5:15 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Rhumbline AdvisersRhumbline Advisers reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 267,933 shares of the biotechnology company'sFebruary 19 at 4:03 AM | marketbeat.comSarepta Therapeutics (SRPT) Expected to Announce Earnings on WednesdaySarepta Therapeutics (NASDAQ:SRPT) will be releasing earnings after the market closes on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=321230)February 19 at 3:38 AM | marketbeat.comAllspring Global Investments Holdings LLC Acquires 84,926 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Allspring Global Investments Holdings LLC increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 16,717.7% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 85,434 shares of the biotechnology company's stock after buFebruary 19 at 3:37 AM | marketbeat.comBraun Stacey Associates Inc. Sells 2,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Braun Stacey Associates Inc. trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,022 shares of the biotechnology comFebruary 18 at 6:12 AM | marketbeat.comAlphaCentric Advisors LLC Sells 15,789 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)AlphaCentric Advisors LLC cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 87.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,211 shares of the biotechnFebruary 17, 2025 | marketbeat.comVan ECK Associates Corp Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Van ECK Associates Corp raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 84,834 shares of the biotechnology company's stockFebruary 17, 2025 | marketbeat.comBanque Pictet & Cie SA Sells 4,059 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Banque Pictet & Cie SA lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 43,986 shares of the biotechnology company's stock after selling 4,059 sharFebruary 15, 2025 | marketbeat.comCapital International Investors Increases Stake in Sarepta Therapeutics IncFebruary 14, 2025 | gurufocus.comSarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit FacilityFebruary 14, 2025 | businesswire.comSarepta Therapeutics' (SRPT) Sell Rating Reiterated at HC WainwrightHC Wainwright restated a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday.February 13, 2025 | marketbeat.comFiera Capital Corp Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Fiera Capital Corp reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 350,329 shares of the biotechnology companFebruary 13, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Earns Hold Rating from Analysts at Deutsche Bank AktiengesellschaftFebruary 13, 2025 | americanbankingnews.comSarepta initiated with a Hold at Deutsche BankFebruary 12, 2025 | markets.businessinsider.comSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial ResultsFebruary 12, 2025 | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLCGladstone Institutional Advisory LLC lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,885 shares of the biotechFebruary 12, 2025 | marketbeat.comSapient Capital LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sapient Capital LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 56.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,540 shares of the biotechnology company's stock after selFebruary 12, 2025 | marketbeat.comDeutsche Bank sets Sarepta stock target at $136, cites risksFebruary 11, 2025 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a report on Tuesday. They set a "hold" rating and a $136.00 target price for the company.February 11, 2025 | marketbeat.comSovran Advisors LLC Buys Shares of 27,015 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sovran Advisors LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 27,015 shares of the biotechnology company's stock, valued at approximatelyFebruary 11, 2025 | marketbeat.comWCM Investment Management LLC Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)WCM Investment Management LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 110.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,977 shares of the biotechnology companyFebruary 11, 2025 | marketbeat.comArrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta TherapeuticsFebruary 10, 2025 | finance.yahoo.comArrowhead and Sarepta close $500 million licensing dealFebruary 10, 2025 | msn.comArrowhead to receives $500M upfront in licensing pact with SareptaFebruary 10, 2025 | markets.businessinsider.com2 Growth Stocks to Buy Hand Over Fist in FebruaryFebruary 9, 2025 | fool.comWhy Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by TobamTobam decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 40.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,922 shares of the biotechnology company's stock after selling 19,968 shares during the quarFebruary 7, 2025 | marketbeat.comEquities Analysts Set Expectations for SRPT Q4 EarningsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities research analysts at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued on Monday, February 3rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology companyFebruary 6, 2025 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its IndustryFebruary 5, 2025 | finance.yahoo.comYorktown Management & Research Co Inc Invests $559,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Yorktown Management & Research Co Inc purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,600 shares of the biotechnology company's stock, valuedFebruary 5, 2025 | marketbeat.comZacks Research Issues Optimistic Forecast for SRPT EarningsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Zacks Research lifted their FY2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earninFebruary 5, 2025 | marketbeat.comabrdn plc Raises Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)abrdn plc raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 6.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 457,695 shares of the biotechnology company's stock afteFebruary 5, 2025 | marketbeat.comSwedbank AB Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Swedbank AB purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 137,400 shares of the biotechnology company's stoFebruary 1, 2025 | marketbeat.comJim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’January 31, 2025 | insidermonkey.comSarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group DisparitiesJanuary 30, 2025 | markets.businessinsider.comSivik Global Healthcare LLC Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sivik Global Healthcare LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the biotechnology company's stock, valued at approximatJanuary 30, 2025 | marketbeat.comQ4 Earnings Estimate for SRPT Issued By William BlairSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Investment analysts at William Blair issued their Q4 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued on Monday, January 27th. William Blair analyst S. Corwin anticipates that the biotechnologyJanuary 30, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC WainwrightHC Wainwright restated a "sell" rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday.January 30, 2025 | marketbeat.comSarepta moves off lows after speaking to RBC on patient deathJanuary 29, 2025 | markets.businessinsider.comSarepta could be down on patient death in FDA database, says RBC CapitalJanuary 29, 2025 | markets.businessinsider.comSarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal yearJanuary 28, 2025 | msn.comSarepta Therapeutics: Buy Rating Affirmed on Positive EMBARK Study Results and Strong Financial OutlookJanuary 28, 2025 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)January 28, 2025 | markets.businessinsider.comBMO maintains Outperform on Sarepta stock, $200 targetJanuary 28, 2025 | msn.comSarepta Therapeutics’ Strong Market Position and Elevidys’ Promising Prospects Drive Buy RatingJanuary 28, 2025 | markets.businessinsider.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.990.60▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼1410▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Genmab A/S News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free Srpt Stock Alerts